Survodutide

Think of GLP-1 drugs like Wegovy as a car with one strong brake on appetite. Survodutide adds a second pedal that also revs up the body's fat-handling and energy use. On the test track (trials) the prototype is performing impressively. It still hasn't passed its full safety certification though, so it isn't road-legal anywhere yet. Any version sold out of a back-alley garage is of completely unknown build quality.

Dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), given by subcutaneous injection. GLP-1R activation suppresses appetite, slows gastric emptying and enhances glucose-dependent insulin secretion. GCGR activation is thought to add increased energy expenditure and reduced hepatic fat. The combination aims to amplify weight loss and improve metabolic and liver disease beyond GLP-1 agonism alone. In preclinical characterisation it delivers near-full GLP-1R activation but only partial GCGR activation at therapeutic exposures.

Research contexts. Not proven uses, and not recommendations.

Genuinely substantial for an unapproved peptide, but still incomplete. Two completed Phase 2 trials met their primary endpoints: a dose-finding obesity trial (le Roux et al., Lancet Diabetes & Endocrinology 2024) showing up to roughly 18-19% mean weight loss over 46 weeks in completers, and a MASH/fibrosis trial (Sanyal et al., NEJM 2024) showing MASH improvement without worsening of fibrosis in up to about 62% of patients on the highest dose versus around 14% on placebo at 48 weeks. The first large Phase 3 obesity trial (SYNCHRONIZE-1, 76 weeks) reported positive results (up to about 16.6% weight loss versus 3.2% placebo on the efficacy estimand). However, the rest of the Phase 3 obesity programme (including a type 2 diabetes trial and a cardiovascular outcomes trial) and the Phase 3 MASH outcome programme (LIVERAGE, LIVERAGE-Cirrhosis) are still ongoing with several trials not yet fully published or completed. Strong mid-stage and emerging late-stage human data exists, but the confirmatory long-term safety and outcomes picture is incomplete and no regulator has reviewed it.

• !Not approved or licensed by the MHRA, FDA, EMA or any other regulator. It remains investigational, so efficacy and long-term safety have not been confirmed by a regulatory review.
• !Gastrointestinal side effects (nausea, vomiting, diarrhoea) are common and titration-dependent, consistent with the incretin drug class.
• !Glucagon receptor agonism can raise heart rate and affect glucose and blood pressure. Long-term cardiovascular and metabolic safety is still being established in dedicated trials.
• !Pivotal Phase 3 obesity and MASH outcome trials are still ongoing. Current weight-loss and liver figures may not fully reflect the eventual licensed picture, and durability after stopping is not yet established.
• !Anything sold online as survodutide is by definition unlicensed and unregulated material of unverified identity, purity, sterility and content. This is a real quality and safety hazard.
• !As with other potent weight-loss agents, loss of lean mass and use without medical supervision are genuine concerns.

Not a licensed UK medicine. Survodutide is investigational with no MHRA marketing authorisation, so it cannot be lawfully sold or prescribed as an approved medicine in the UK. Legitimate access is only through authorised clinical trials. It is not a controlled drug, but supplying or selling an unlicensed medicinal product for human use is restricted under the Human Medicines Regulations 2012. Material marketed online as a research chemical or not for human consumption is unlicensed, unregulated and sits entirely outside any quality or safety oversight.

• NCT04771273· Phase 2· Completed

  A Study to Test Safety and Efficacy of Survodutide (BI 456906) in Adults With NASH/MASH and Fibrosis (F1-F3)

  MASH/fibrosis trial published in NEJM 2024.

• NCT06066515· Phase 3· Reported topline (76 weeks); full publication pending

  SYNCHRONIZE-1: Phase 3 trial of survodutide for obesity/overweight without type 2 diabetes

  Up to ~16.6% weight loss vs 3.2% placebo on the efficacy estimand.

• NCT06632444· Phase 3· Ongoing

  LIVERAGE: Phase 3 trial of survodutide in MASH with moderate-to-advanced fibrosis (F2-F3)

  Pivotal MASH outcome trial. NCT identifier should be re-verified before publication.

1. 01
   A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis — Sanyal AJ, et al., New England Journal of Medicine 2024;391(4):311-319 (2024)

   Phase 2 MASH/fibrosis trial (48 weeks); met primary endpoint of MASH improvement without worsening fibrosis. Basis for FDA Breakthrough Therapy designation.

2. 02
   Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial — le Roux CW, et al., The Lancet Diabetes & Endocrinology 2024;12(3):162-173 (2024)

   Phase 2 dose-finding obesity trial; up to ~18-19% mean weight loss over 46 weeks in completers.

3. 03
   BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist — Zimmermann T, et al., Molecular Metabolism (2022)

   Preclinical pharmacology: near-full GLP-1R agonism with partial GCGR agonism.

4. 04
   Survodutide Phase III SYNCHRONIZE-1 obesity trial results (company announcement) — Boehringer Ingelheim, Boehringer Ingelheim press release (2026)

   Reported up to ~16.6% weight loss over 76 weeks vs 3.2% placebo (efficacy estimand). Topline/conference data; full publication pending.